Lonza Group AG is a Swiss multinational manufacturing company based in Basel, specializing in contract development and manufacturing services for the pharmaceutical, biotechnology, and nutrition sectors. Founded in 1897, Lonza has evolved from its origins in hydroelectric power to become a leader in biopharmaceutical manufacturing, operating over thirty development and manufacturing sites worldwide.
As a pure-play contract development and manufacturing organization (CDMO), Lonza offers a wide range of services, including biologics manufacturing, small molecules production, bioconjugates, and cell and gene therapies. The company also provides drug product services and detection systems for the bioscience sector. Lonza has established significant partnerships with major pharmaceutical companies, including a notable collaboration with Moderna for the production of its COVID-19 vaccine. With a strong market position, Lonza plays a crucial role in the growth of outsourced drug manufacturing and the development of innovative therapies.
Moderna is a pharmaceutical and biotechnology company pioneering mRNA medicines to prevent and treat diseases, developing vaccines and therapeutics across multiple indications.
Developer and manufacturer of bio-pharmaceutical products intended to offer innovative development and clinical or commercial manufacturing of large molecule APIs from mammalian cell culture, microbial fermentation and plasmid DNA. The company provides therapeutic proteins and antibodies, cell culture development, purification development, troubleshooting existing processes and analytical development support services as well as cell banking, microbial, mammalian and support services, thereby providing clients with microbial and mammalian expression systems to support scale-up at every stage.